Coronary heart disease and type 2 diabetes metabolomic signatures in the Middle East
Metabolomic profiling has the potential for the early detection of metabolic alterations that precede clinical symptoms of T2D and CHD in the presence of T2D. Risk scores showed great performance in predicting T2D and CHD, but longitudinal data are required to provide evidence for disease risk. Early detection allows timely interventions and improved management strategies for both T2D and CHD patients.
Authors
- Vidya Mohamed‐Ali (ORCID: https://orcid.org/0000-0003-1532-3817)
- Keivin Isufaj (ORCID: https://orcid.org/0000-0001-5508-4430)
- Mohammed Al‐Maadheed (ORCID: https://orcid.org/0000-0001-5517-0128)
- Ayman El‐Menyar (ORCID: https://orcid.org/0000-0003-2584-953X)
- Jassim Al Suwaidi (ORCID: https://orcid.org/0000-0002-5299-9106)
- Mohamed Elshrif (ORCID: https://orcid.org/0000-0003-0092-8258)
- Mohamad Saad (ORCID: https://orcid.org/0000-0001-6357-8502)
- Alka Beotra (ORCID: https://orcid.org/0000-0001-9767-2724)
- Ehsan Ullah (ORCID: https://orcid.org/0000-0002-9881-6731)
Institutions
- Hamad bin Khalifa University (QA)
- Weill Cornell Medical College in Qatar (QA)
- Anti-Doping Laboratory (QA)
- Hamad Medical Corporation (QA)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2025-11-17
- DOI
- https://doi.org/10.3389/fendo.2025.1531525
- Primary Topic
- Metabolomics and Mass Spectrometry Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Anti-Doping Laboratory Qatar
- Medical Research Council